Propranolol-Induced Psoriasis-Like Model Development Services
The propranolol-induced psoriasis-like model mimics the features of epidermal damage observed in human psoriasis, in particular, hyperkeratosis, parakeratosis, and acanthosis. At Ace Therapeutics, we provide propranolol-induced psoriasis-like model development and preclinical anti-psoriasis drug efficacy valuation services.
Introduction to Propranolol-Induced Psoriasis-Like Models
In 1978, Gaylarde first observed that topical application of propranolol to the skin of guinea pigs could induce histopathological changes similar to human psoriasis. Application of propranolol, which acts as a non-selective β-adrenergic receptor blocker, may reduce intracellular cAMP levels, accelerate keratinocyte proliferation, and thereby induce psoriasis-like phenotypes, such as hyperkeratosis and acanthosis. After decades of rigorous scientific validation, the propranolol-induced psoriasis-like guinea pig model has been established and used to evaluate the preclinical efficacy of anti-psoriasis drugs. The propranolol-induced psoriasis-like model is easy to establish, has a short induction time, and effectively mimics the main epidermal changes seen in human psoriasis.
Fig. 1. IMMH002 ameliorates propranolol induced psoriasis in guinea pig. (Jin J, et al., 2020)
Development and Validation of Propranolol-Induced Psoriasis-Like Models
Uinea pigs weighing between 250 g and 400 g are selected for model development in accordance with the validation protocol of Ace Therapeutics. Our experts apply 5% propranolol emulsion to the auricular dorsal surfaces of the guinea pigs twice daily for three weeks to induce psoriasis-like phenotypes. We also provide animal model validation services, which include the characterization of pathological features such as erythema, scaling, skin thickening, and epidermal hyperplasia.
Preclinical Anti-Psoriasis Drug Efficacy Evaluation Based on Propranolol-Induced Psoriasis-Like Models
| Service Options | Description |
| Assessment of Psoriasis Lesions | We help clients assess skin lesions by observing the erythema, induration, and scaling on the propranolol treated-guinea pigs. |
| Histopathological Profiling Services | Our scientists use HE and IHC staining to analyze keratinocyte proliferation and immune cell infiltration. |
| Immunological Profiling Services | We perform multiple molecular biology experiments to measure inflammatory cytokine expression levels, immune cell populations, and signaling pathway activation status. |
Our Advantages in Propranolol-Induced Psoriasis-Like Model Development
Extensive Expertise: Ace Therapeutics specializes in developing propranolol-induced psoriasis-like models that closely resemble human psoriasis phenotypes, including hyperkeratosis, parakeratosis, and acanthosis.
Standardized Platform: Ace Therapeutics has well-established modeling methods using a validated 3-week induction protocol to support drug efficacy evaluation.
Tailored Drug Efficacy Evaluation Strategies: Our team designs customized drug efficacy evaluation protocols that integrate psoriasis-specific endpoints and mechanism-driven assays, ensuring alignment with distinct research objectives and adaptability to diverse anti-psoriasis drugs.
At Ace Therapeutics, we support clients from pharmaceutical and academic organizations to develop novel anti-psoriasis drugs. To explore how the propranolol-induced psoriasis-like model can accelerate your drug development pipeline, please contact us.
Reference
- Jin J, et al. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharm Sin B. 2020; 10(2):276-288.